While evidence suggests that Tau reduction can block AD pathology progression (Roberson et al., 2007), indicating that Tau‐targeted strategies might be of interest for AD therapy (Gotz et al., 2012), the safety and/or potential side effect(s) of these approaches is not well studied. The gene discussed is MAPT; the disease is Alzheimer disease.